Exponent Inc. Appoints New Director, Sees Departure

Ticker: EXPO · Form: 8-K · Filed: Mar 1, 2024 · CIK: 851520

Exponent INC 8-K Filing Summary
FieldDetail
CompanyExponent INC (EXPO)
Form Type8-K
Filed DateMar 1, 2024
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: board-changes, director-appointment, director-departure

TL;DR

Exponent Inc. board shakeup: Dr. Wood out, Dr. Webb in until 2026.

AI Summary

Exponent Inc. announced on February 26, 2024, the departure of director Dr. Steven D. Wood. Concurrently, the company elected Dr. Michael L. T. Webb as a new Class III director, effective immediately, to serve until the 2026 annual meeting of stockholders. Dr. Webb will also join the Audit Committee and the Compensation Committee.

Why It Matters

The appointment of a new director and the departure of another can signal shifts in board strategy or governance, potentially impacting future company decisions and performance.

Risk Assessment

Risk Level: low — The filing reports routine board changes and does not indicate any significant financial distress or operational issues.

Key Numbers

Key Players & Entities

FAQ

What was the effective date of Dr. Steven D. Wood's departure?

The filing indicates Dr. Steven D. Wood's departure was effective February 26, 2024.

What is the term length for the newly elected director, Dr. Michael L. T. Webb?

Dr. Michael L. T. Webb was elected as a Class III director and will serve until the 2026 annual meeting of stockholders.

Which committees will Dr. Michael L. T. Webb join?

Dr. Michael L. T. Webb will join the Audit Committee and the Compensation Committee.

What is Exponent Inc.'s principal executive office address?

Exponent Inc.'s principal executive office is located at 149 Commonwealth Drive, Menlo Park, California 94025.

What is the filing date of this 8-K report?

This 8-K report was filed on March 1, 2024.

Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 11.8 · Accepted 2024-03-01 16:12:50

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EXPONENT, INC. Date: March 1, 2024 By: /s/ Richard L. Schlenker Richard L. Schlenker Executive Vice President, Chief Financial Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing